Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellula, page-3

We also studied the efficacy of the combination of Y90 RMS and sorafenib in our retrospective analysis. The median OS from the start of treatment with sorafenib was 19.52 months (95% CI, 9.23–33.68 months), and OS rates were 62.3% at 1 year and 31.7% at 2 years, according to Kaplan–Meier analysis. These findings are impressive when compared with those of the SHARP trial (median OS, 10.7 months; 1-year OS rate, 44%)1 and the Sorafenib Asia–Pacific trial (median OS, 6.5 months).3 PFS in our study was 6.63 months, which is 1 month longer than that reported in the SHARP trial. We also observed a partial response in 19% of patients and stable disease in 81% of patients. This is superior to data reported in the SHARP trial, in which partial response was recorded in 2% of patients and stable disease in 71% of patients.1

Great find Cafa, thanks for sharing. Small retrospective study, but can't help but think this bodes well for SARAH. A dual SIRT-Sorafenib arm would have been nice to include.